Anti-TNF (Local Administration)
Dupuytren's Disease (Early Stage)
Key Facts
About 180 Life Sciences
180 Life Sciences is pioneering new approaches to treating inflammatory and fibrotic diseases through a diversified pipeline of clinical and pre-clinical programs. Its core strategy involves repurposing and optimizing anti-TNF therapies for localized fibrotic conditions and exploring synthetic cannabinoids for pain and inflammation. The company faces the challenges typical of a clinical-stage biotech but is led by a team with deep experience in drug development and immunology.
View full company profileAbout 180 Life Sciences
180 Life Sciences is pioneering new approaches to treating inflammatory and fibrotic diseases through a diversified pipeline of clinical and pre-clinical programs. Its core strategy involves repurposing and optimizing anti-TNF therapies for localized fibrotic conditions and exploring synthetic cannabinoids for pain and inflammation. The company faces the challenges typical of a clinical-stage biotech but is led by a team with deep experience in drug development and immunology.
View full company profileAbout 180 Life Sciences
180 Life Sciences is pioneering new approaches to treating inflammatory and fibrotic diseases through a diversified pipeline of clinical and pre-clinical programs. Its core strategy involves repurposing and optimizing anti-TNF therapies for localized fibrotic conditions and exploring synthetic cannabinoids for pain and inflammation. The company faces the challenges typical of a clinical-stage biotech but is led by a team with deep experience in drug development and immunology.
View full company profile